DE69905489D1 - Protein c zur behandlung von sichelzellanämie und thalassämie - Google Patents

Protein c zur behandlung von sichelzellanämie und thalassämie

Info

Publication number
DE69905489D1
DE69905489D1 DE69905489T DE69905489T DE69905489D1 DE 69905489 D1 DE69905489 D1 DE 69905489D1 DE 69905489 T DE69905489 T DE 69905489T DE 69905489 T DE69905489 T DE 69905489T DE 69905489 D1 DE69905489 D1 DE 69905489D1
Authority
DE
Germany
Prior art keywords
thalassemia
protein
treatment
sickle
lemenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69905489T
Other languages
English (en)
Other versions
DE69905489T2 (de
Inventor
Lee Um
Betty Yan
Gail Utterback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiome Pharma Corp
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69905489D1 publication Critical patent/DE69905489D1/de
Publication of DE69905489T2 publication Critical patent/DE69905489T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69905489T 1998-11-23 1999-11-16 Protein c zur behandlung von sichelzellanämie und thalassämie Expired - Lifetime DE69905489T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10947498P 1998-11-23 1998-11-23
PCT/US1999/026958 WO2000030676A1 (en) 1998-11-23 1999-11-16 Method of treating sickle cell disease and thalassemia

Publications (2)

Publication Number Publication Date
DE69905489D1 true DE69905489D1 (de) 2003-03-27
DE69905489T2 DE69905489T2 (de) 2003-09-11

Family

ID=22327841

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69905489T Expired - Lifetime DE69905489T2 (de) 1998-11-23 1999-11-16 Protein c zur behandlung von sichelzellanämie und thalassämie

Country Status (14)

Country Link
US (1) US6372213B2 (de)
EP (1) EP1133314B1 (de)
JP (1) JP2002530352A (de)
CN (1) CN1326357A (de)
AT (1) ATE232739T1 (de)
AU (1) AU1723200A (de)
BR (1) BR9915572A (de)
CA (1) CA2351591A1 (de)
DE (1) DE69905489T2 (de)
DK (1) DK1133314T3 (de)
ES (1) ES2192874T3 (de)
IL (1) IL142247A0 (de)
WO (1) WO2000030676A1 (de)
ZA (1) ZA200102727B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290553A1 (en) * 2000-09-18 2002-04-02 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
EP2815749A1 (de) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
CN106399478B (zh) 2016-08-31 2024-09-03 桂林优利特医疗电子有限公司 一种荧光探针PCR法快速检测α/β-地中海贫血的试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
BR9809304B1 (pt) * 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
EP1133314A1 (de) 2001-09-19
WO2000030676A1 (en) 2000-06-02
ZA200102727B (en) 2002-09-25
DE69905489T2 (de) 2003-09-11
AU1723200A (en) 2000-06-13
ATE232739T1 (de) 2003-03-15
US20020012662A1 (en) 2002-01-31
EP1133314B1 (de) 2003-02-19
ES2192874T3 (es) 2003-10-16
CA2351591A1 (en) 2000-06-02
IL142247A0 (en) 2002-03-10
US6372213B2 (en) 2002-04-16
JP2002530352A (ja) 2002-09-17
DK1133314T3 (da) 2003-04-14
BR9915572A (pt) 2001-08-14
CN1326357A (zh) 2001-12-12

Similar Documents

Publication Publication Date Title
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69508192D1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
DE69941586D1 (de) Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
ATE311226T1 (de) Die glycin-betain für seine antithrombotische verwendung
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
ATE235915T1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.
ATE311901T1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
ATE258550T1 (de) Oxirancarbonsäuren für die behandlung von diabetes
WO1998023574A8 (en) Asiatic acid derivatives and medicines for treating wounds, which contains the same
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CARDIOME PHARMA CORP., VANCOUVER, CA

8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN